---
layout: minimal-medicine
title: Asciminib
---

# Asciminib
### Generic Name
Asciminib

### Usage
Asciminib is a tyrosine kinase inhibitor (TKI) specifically used to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).  It's primarily indicated for patients in the chronic phase of the disease who have already received treatment with two or more other TKIs.  A notable secondary use is for treating chronic-phase Ph+ CML patients carrying the T315I mutation, a mutation that often makes the disease resistant to other TKIs.  Asciminib offers a targeted approach to combatting this challenging form of leukemia.


### Dosage

**Adult Dosage:**

* **Ph+ CML in chronic phase (previously treated with two or more TKIs):** The usual oral dose is either 80 mg once daily or 40 mg twice daily. Treatment continues until the disease progresses or intolerable side effects occur.
* **Ph+ CML in chronic phase with the T315I mutation:** The usual oral dose is 200 mg twice daily.  Treatment is continued until disease progression or unacceptable toxicity develops.

**Pediatric Dosage:** The safety and efficacy of asciminib in pediatric patients have not been established.

**Dosage Adjustments:**  Dosage adjustments may be necessary based on several factors.  For example, patients experiencing certain side effects might require dose reductions or temporary treatment interruptions.  Specific adjustments are made based on the severity of adverse reactions such as myelosuppression (low blood cell counts), pancreatic toxicity, or other significant side effects.  Consult the prescribing information for detailed guidelines on dosage adjustments for hepatic or renal impairment.


### Side Effects

**Common Side Effects:**  The frequency and severity of side effects can vary. Common side effects include headache, hypertension (high blood pressure), diarrhea, nausea, fatigue, and decreased blood cell counts (neutropenia, thrombocytopenia, anemia).  Additional common side effects include increased levels of liver enzymes (ALT, AST), increased cholesterol and triglycerides, and musculoskeletal pain.

**Serious but Less Common Side Effects:**  More serious, though less frequent, side effects can include pancreatitis (inflammation of the pancreas),  cardiovascular events (such as heart failure or arrhythmias), and severe allergic reactions (hypersensitivity).  Any new or worsening symptoms should be reported to a healthcare provider immediately.

**Important Note:** This is not an exhaustive list.  Consult a healthcare professional for a comprehensive understanding of potential side effects and to address any concerns.


### How it Works

Asciminib is a highly selective inhibitor of ABL tyrosine kinase,  a protein crucial in the development and progression of Ph+ CML.  By binding to the myristoyl pocket of the ABL kinase, asciminib prevents the kinase from functioning correctly. This action interrupts signaling pathways essential for leukemia cell growth and survival, ultimately leading to a reduction in the number of leukemic cells.  Importantly, asciminib has demonstrated activity against various BCR-ABL1 mutations, including the challenging T315I mutation, which makes it a valuable treatment option for patients with resistant disease.


### Precautions

* **Pregnancy and Breastfeeding:** Asciminib can harm a developing fetus.  Women of childbearing age should use effective contraception during treatment and for one week after the last dose.  Breastfeeding should be avoided during treatment and for one week after the final dose.
* **Drug Interactions:** Asciminib can interact with other medications, particularly those metabolized by the CYP3A4 and CYP2C9 enzymes or transported by P-glycoprotein (P-gp).  Consult a healthcare provider about any medications you are currently taking before starting treatment with asciminib.
* **Hypersensitivity:** Individuals with a history of hypersensitivity reactions to asciminib or its components should avoid using this medication.
* **Myelosuppression:**  Asciminib can suppress bone marrow function leading to low blood cell counts. Regular blood tests are essential to monitor for this side effect.
* **Cardiovascular Effects:**  Asciminib can increase the risk of hypertension and other cardiovascular complications. Blood pressure monitoring is crucial.
* **Hepatic and Renal Impairment:** Dosage adjustments may be needed for patients with impaired liver or kidney function.



### FAQs

* **Q: Can I take asciminib with food?** A: No.  Asciminib should be taken without food. Avoid eating for at least 2 hours before and 1 hour after taking the medication.

* **Q: What should I do if I miss a dose?** A: If you miss a dose of asciminib, refer to the prescribing information for guidance on whether to skip the missed dose or take it as soon as possible, depending on the prescribed dosing schedule.  Do not double the dose.

* **Q: How should I store asciminib?** A: Store asciminib as directed on the medication label, typically at room temperature and away from moisture and light.

* **Q: Are there any long-term effects of asciminib?** A:  Long-term effects are still being studied. Regular monitoring by your healthcare provider is essential to detect and manage any potential long-term side effects.

* **Q:  Is asciminib suitable for everyone with CML?** A: No, asciminib is specifically indicated for adult patients with chronic-phase Ph+ CML who have failed two or more prior TKIs, or those with the T315I mutation.  Your healthcare provider will determine if it's the right treatment for you.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice. Always consult your healthcare provider before starting or stopping any medication. The information provided here is a summary and may not include all the details found in the official prescribing information.  Always refer to the complete prescribing information for the most accurate and up-to-date guidance.
